Cargando…

Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability

SIMPLE SUMMARY: Previous studies reporting large gene panels in breast cancer have mainly reported on the contribution of additional genes compared to BRCA1/2. We have shown a very large differential additional effect from non-BRCA genes dependent on a priori likelihood of BRCA1 and BRCA2 combined....

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, D. Gareth, van Veen, Elke M., Woodward, Emma R., Harkness, Elaine F., Ellingford, Jamie M., Bowers, Naomi L., Wallace, Andrew J., Howell, Sacha J., Howell, Anthony, Lalloo, Fiona, Newman, William G., Smith, Miriam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394249/ https://www.ncbi.nlm.nih.gov/pubmed/34439310 http://dx.doi.org/10.3390/cancers13164154

Ejemplares similares

Extended gene panel testing in lobular breast cancer
por: van Veen, Elke M., et al.
Publicado: (2021)

Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer
por: Hyder, Zerin, et al.
Publicado: (2020)

Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer
por: Woodward, Emma R., et al.
Publicado: (2021)

High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer
por: Evans, D Gareth, et al.
Publicado: (2022)

Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers
por: Evans, DG, et al.
Publicado: (2017)

Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women
por: Evans, D. Gareth, et al.
Publicado: (2021)

Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
por: Evans, D Gareth, et al.
Publicado: (2008)

A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer
por: Evans, D.Gareth R., et al.
Publicado: (2018)

The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?
por: Evans, D. Gareth, et al.
Publicado: (2021)

Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer
por: Evans, D.Gareth, et al.
Publicado: (2021)

Metaplastic breast cancer and BRCA1: first strong evidence of a link
por: Evans, D. Gareth R, et al.
Publicado: (2023)

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
por: Evans, D. Gareth, et al.
Publicado: (2019)

Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?
por: Prosperi, Mattia CF, et al.
Publicado: (2014)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives
por: Bennett, Sarah, et al.
Publicado: (2021)

Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels
por: Crosbie, Emma J., et al.
Publicado: (2020)

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants
por: Evans, D. Gareth R., et al.
Publicado: (2019)

Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
por: Gareth Evans, D, et al.
Publicado: (2004)

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Gene panel testing for breast cancer should not be used to confirm syndromic gene associations
por: Evans, D. Gareth, et al.
Publicado: (2018)

MSH2 is the very young onset ovarian cancer predisposition gene, not BRCA1
por: Flaum, Nicola, et al.
Publicado: (2023)

BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
por: Kitson, Sarah J., et al.
Publicado: (2020)

Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women
por: Evans, D. Gareth, et al.
Publicado: (2015)

Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores
por: Evans, D. G., et al.
Publicado: (2016)

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
por: Evans, D G R, et al.
Publicado: (2010)

A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density
por: Brentnall, Adam R., et al.
Publicado: (2019)

Magnitude and attributed reasons for adult weight gain amongst women at increased risk of breast cancer
por: Pegington, Mary, et al.
Publicado: (2022)

Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987–2020)
por: Howell, Anthony, et al.
Publicado: (2020)

Implementing Risk-Stratified Breast Screening in England: An Agenda Setting Meeting
por: McWilliams, Lorna, et al.
Publicado: (2022)

Assessment of mismatch repair deficiency in ovarian cancer
por: Crosbie, Emma J, et al.
Publicado: (2021)

Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?
por: Leventea, Eleni, et al.
Publicado: (2021)

Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers
por: Evans, D Gareth, et al.
Publicado: (2022)

Polygenic risk scores and breast cancer risk prediction
por: Roberts, Eleanor, et al.
Publicado: (2023)

Increased risk of breast cancer in neurofibromatosis type 1: current insights
por: Howell, Sacha J, et al.
Publicado: (2017)

Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives
por: Evans, D Gareth R, et al.
Publicado: (2013)

Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)
por: Gareth Evans, D., et al.
Publicado: (2023)

Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)
por: Gareth Evans, D., et al.
Publicado: (2023)

Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality
por: Evans, D. G., et al.
Publicado: (2016)

The role of prior probability in forensic assessments
por: Thompson, William C., et al.
Publicado: (2013)

Update of Prior Probabilities by Minimal Divergence
por: Naudts, Jan
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vnuhse9oj6hmp1dn7vndh099te